ZDHHC13

Across TCGA pan-cancer cohorts, ZDHHC13 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ZDHHC13’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZDHHC13 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ZDHHC13 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, LUAD, and CCRCC are the cancer types where ZDHHC13 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZDHHC13 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−0.668	<.001	11	view →
LUAD	Male	III,IV	+0.650	<.001	9	view →
CCRCC	All	All	+0.293	<.001	9	view →
LSCC	Male	All	+0.549	<.001	8	view →
PDAC	Male	IV	+0.825	.003	2	view →
COAD	Female	IV	−0.450	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ZDHHC13–HNSC

Open the HNSC breakdown →